[Skip to Content]
[Skip to Content Landing]
August 2, 1930


JAMA. 1930;95(5):345-346. doi:10.1001/jama.1930.02720050033013

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


When cinchophen, or phenylcinchoninic acid, was introduced into therapeutics, about 1908 (reinforced by the trade name "Atophan"—the tophi remover), its striking effect on the elimination of uric acid captured the clinical imagination, which was at that time perhaps somewhat overconscious of uric acid. The product attained immediate popularity. The uric acid complex receded, and it was soon seen that atophan belied its name, for the tophi proved unreasonable and refused to be removed. The drug was found, however, to be an effective analgesic, much like the salicylates, with which it has many points of similarity. Since the taste is different, the popularity of cinchophen continued to increase, so much so that it achieved a place in the United States Pharmacopeia. Various esters and derivatives were advertised extensively for the benefit of those who do not like the flavor of cinchophen and incidentally for the benefit of the manufacturers, who could

First Page Preview View Large
First page PDF preview
First page PDF preview